Sanofi - new suitor for Actelion?

ReutersNewsPublished: December 14, 20162 views
Published: December 14, 2016

After Johnson & Johnson ended its bid, France's Sanofi is reported to be the next suitor in waiting for a tie-up with Europe's largest biotechnology drug maker, Actelion. As Ciara Lee reports, a deal could value Actelion at as much as $30 billion.

Be the first to suggest a tag